Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Newbury Pharmaceuticals

1.19 SEK

+0.42 %

Less than 1K followers

NEWBRY

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Newbury Pharmaceuticals

2022202320242025
Revenue5.510.336.831.6
growth-%86.1 %258.6 %-14.3 %
EBITDA-13.7-18.3-12.3-16.3
EBIT-3.9-19.6-14.1-22.0
Profit before taxes-3.9-19.4-15.4-23.6
Net income-3.9-19.4-15.4-23.9
EPS-0.00-1.00-0.79-0.88
Dividend0.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %
Login required

This content is only available for logged in users

Create account

Profitability and return on capital

2022202320242025
EBITDA-%-247.5 %-178.5 %-33.5 %-51.6 %
EBIT-%-70.7 %-190.7 %-38.2 %-69.6 %
ROE-5.7 %-39.3 %-29.7 %-55.9 %
ROI-4.5 %-26.6 %-17.0 %-30.9 %
Login required

This content is only available for logged in users

Create account
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.